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AbstrACt
Introduction Vitamin B12 deficiency is widely prevalent 
across many low- and middle- income countries, especially 
where the diet is low in animal sources. While many 
observational studies show associations between B
12 
deficiency in pregnancy and infant cognitive function 
(including memory, language and motor skills), evidence 
from clinical trials is sparse and inconclusive.
Methods and analysis This double- blind, multicentre, 
randomised controlled trial will enrol 720 vegetarian 
pregnant women in their first trimester from antenatal 
clinics at two hospitals (one in India and one in Nepal). 
Eligible mothers who give written consent will be 
randomised to receive either 250 mcg methylcobalamin 
or 50 mcg (quasi control), from enrolment to 6 months 
post- partum, given as an oral daily capsule. All mothers 
and their infants will continue to receive standard 
clinical care. The primary trial outcome is the offspring’s 
neurodevelopment status at 9 months of age, assessed 
using the Development Assessment Scale of Indian Infants. 
Secondary outcomes include the infant’s biochemical 
B
12 status at age 9 months and maternal biochemical 
B12 status in the first and third trimesters. Maternal 
biochemical B12 status will also be assessed in the first 
trimester. Modification of association by a priori identified 
factors will also be explored.
Ethical considerations and dissemination The study 
protocol has been approved by ethical committees at 
each study site (India and Nepal) and at University College 
London, UK. The study results will be disseminated to 
healthcare professionals and academics globally via 
conferences, presentations and publications. Researchers 
at each study site will share results with participants 
during their follow- up visits.
trial registration number
CTRI/2018/07/015048 (Clinical Trial Registry of India); 
NCT04083560 ( ClinicalTrials. gov)
IntroduCtIon
Malnutrition during pregnancy is a global 
health problem. Micronutrient deficiencies 
are associated with adverse developmental 
outcomes in children, including poorer 
neurocognitive functioning which can poten-
tially lead to poorer educational achievement 
and economic prospects.1 2
Vitamin B12 deficiency is prevalent across 
many low- and middle- income countries 
(LMICs).3–6 Partaking in a vegetarian diet, or 
one low in animal food sources, is a key risk 
factor in developing B12 deficiency.
7 8 Suffi-
cient B12 intake during pregnancy is vital for 
fetal brain development.9 Deficiency of B12 in 
pregnancy is linked to infant birth defects, 
intrauterine growth restriction, preterm 
strengths and limitations of this study
 ► Large- scale, multicentre, randomised controlled, 
double- blind trial across a low- and middle- income 
country and low- income country to determine the 
efficacy of maternal vitamin B
12 supplementation 
during pregnancy on neurodevelopmental outcomes 
6 month post- partum.
 ► Study design benefits from the preceding qualitative 
patient and public involvement and nested quali-
tative substudy, ensuring participant feedback and 
process evaluation to optimise trial conduct.
 ► The study is being conducted across two diverse 
socio- demographic populations to increase gener-
alisability of study findings.
 ► Normal/routine care differs at the two sites, which 
could lead to differences in the conduct and mon-
itoring of the trial.
 ► Health system regulatory structures differ in the two 
countries.
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delivery and neural tube defects.10–14 Many observational 
studies have shown associations between B12 deficiency 
during pregnancy or early infancy with subsequent poorer 
infant neurodevelopment15 and cognitive function16 17 
including memory,18 language and motor skills.19
There is limited evidence from randomised controlled 
trials (RCTs) regarding the effect of vitamin B12 supple-
mentation and infant cognitive outcomes.20–22 An infant 
supplementation trial observed neurodevelopmental 
benefits of infant B12 supplementation with folate, and 
documented 0.45 (95% CI 0.19 to 0.73) and 0.28 (95% 
CI 0.02 to 0.54) higher SD- units in the domains of gross 
motor and problem- solving functioning, respectively.22 
However, in this study there was no significant benefit of 
giving vitamin B12 or folic acid alone on early child devel-
opment (with the exception of vitamin B12 in relation to 
gross motor functioning22). In another trial, maternal 
vitamin B12 supplementation given as 50 mcg a day from 
<14 weeks’ gestation through to 6 weeks post- partum did 
not improve infant neurodevelopmental outcomes at 9 
months.21 In this trial hyperhomocysteinaemia (a marker 
of B12 insufficiency) during pregnancy was negatively asso-
ciated with infant cognitive outcomes. The study docu-
mented a deterioration in biochemical B12 status in the 
placebo group, while the rise in B12 status in the supple-
mented group (50 mcg) was inconsistent (no significant 
difference between first and third trimester levels). Addi-
tionally, a high rate of participant attrition (51.4%), poor 
monitoring of supplement compliance, a lack of biochem-
ical improvement in B12 status in the supplemented group 
of mothers and lack of infant biochemical evaluation for 
B12 status in later infancy, further limit the inferences that 
can be drawn from this trial. Other studies that assessed a 
250 mcg dose of B12 per day throughout pregnancy until 
3 months’ post- partum in Bangladesh,23 and >2000 mcg 
from 17 to 34 weeks’ gestation in India24 did not evaluate 
neurodevelopment outcomes in infancy. Hence, there is 
insufficient evidence concerning timing, dose, duration 
and efficacy of B12 supplementation with reference to 
infant neurodevelopment.
To address this evidence gap, we are conducting a 
double- blind, multicentre, RCT in one LMIC (India) and 
one low- income country (Nepal), which will evaluate the 
efficacy of 250 mcg/day vitamin B12 supplementation in 
vegetarian mothers from the first trimester to 6 months’ 
post- partum on infant neurodevelopmental outcomes 
at age 9 months. Although, several published protocols 
report ongoing work on B12 supplementation in India 
and Nepal,25 26 the proposed work differs significantly in 
several ways.
First, we specifically chose to supplement vegetarian 
women, as they are a high- risk population due to their 
low B12 intake, and as such have a high prevalence of B12 
deficiency. Second, an interventional dose of 250 mcg was 
chosen because it has been shown in an earlier trial to 
improve B12 levels in pregnancy
23 (although infant neuro-
development was not assessed in this trial). Third, we 
chose 50 mcg B12 per day as a quasi- control group as this 
dose has been shown to prevent deterioration in B12 status 
during pregnancy in India.21 Furthermore, given the 
progressive decline in B12 levels throughout pregnancy 
(documented in the placebo group of earlier trials21 22), 
and the potentially serious neonatal consequences of 
severe B12 deficiency highlighted above, a pure placebo 
control was thought to be unethical.
AIMs And objECtIvEs
Primary objective
To determine the effect of 250 mcg versus 50 mcg daily 
oral vitamin B12 supplementation of pregnant women 
from the first trimester to 6 months post- partum on infant 
neurodevelopment at age 9 months.
secondary objectives
To determine the effect of 250 mcg versus 50 mcg of oral 
vitamin B12 supplementation in pregnancy and 6 months 
post- partum on biochemical parameters of B12 status 
(vitamin B12 levels, homocysteine and holotranscobal-
amin) in mothers at the end of the third trimester and in 
infants at age 9 months.
tertiary objectives
1. To evaluate the influence of the following effect 
modifiers:
a. Socio- economic indicators (income, education, 
profession) on the relationship between maternal 
B12 status, supplementation and infant neurodevel-
opment;
b. Type of milk feeding on the infant vitamin B12 status 
and infant neurodevelopment at 9 months;
c. Maternal dietary B12 intake with maternal and infant 
B12 status, supplementation and infant neurodevel-
opment;
d. Infant complementary feeding with infant vitamin 
B12 status and infant neurodevelopment at 9 months;
e. Maternal and infant B12 status and neurodevelop-
ment at 9 months after birth.
2. To determine the interaction of maternal iron and 
vitamin D status with the relationship between infant 




The study is registered as a primary clinical trial at the WHO 
International Clinical Trials Registry Platform through the 
Clinical Trial Registry of India (CTRI/2018/07/015048) 
and at  ClinicalTrials. gov (ID NCT04083560).
setting
This study includes two sites: Delhi, India and Kath-
mandu, Nepal. Both countries have documented a high 
prevalence of B12 deficiency.
5 6
Participants
Mothers will be recruited from the (1) Sitaram Bhartia 
Institute of Science and Research (SBISR), New Delhi, 
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India, a privately- funded, tertiary hospital catering for a 
high- and middle- income population, with approximately 
700 deliveries annually; and (2) Paropakar Maternity 
and Women’s Hospital (PMWH), Kathmandu, Nepal, 
a government hospital catering for a poorer socio- 
economic area with approximately 22 000 deliveries 
annually. Our earlier work (2011 to 2014) documented 
that the majority of mothers delivering at SBISR were 
well- educated (96.8% college education), employed 
(63.2%) living in high income (annual income 16 000 
US$) nuclear families (57.9%).27 A directly comparable 
data set was not available from PMWH.
Feasibility data and preliminary work
Feasibility of data and preliminary qualitative work was 
conducted for the trial in 2017 to 2018. Feasibility of 
recruitment within the given timelines was studied on 
the basis of previous data available from the study sites. 
The lead author (JN) examined neurodevelopmental 
outcomes of 413 babies born at SBISR in a cohort study 
conducted between 2011 and 2014. The project had a 
similar design to that proposed for this trial, using ante-
natal recruitment and post- delivery infant neurodevelop-
mental follow- up.27 Approximately two- thirds (67%) of 
subjects were retained to follow- up in the cohort study. 
The loss to follow- up (33%) and speed of recruitment 
have been considered in the sample size calculations and 
the recruitment timeline for this trial. No similar recruit-
ment and retention data were available from PMWH.
Patient and public involvement
To represent the participants’ perspective, a patient and 
public involvement (PPI) panel was established consisting 
of four parent pairs (two pairs per site) who had delivered 
a baby within the previous 2 years. One parent pair has 
continued to be involved with the project development 
and the Trial Oversight Committee. We conducted an 
exploratory study with pregnant mothers at both study 
sites to better understand the factors likely to influence 
the uptake and implementation of the proposed inter-
vention, and proposed barriers to implementation (data 
unpublished). This qualitative study established that most 
respondents were unaware of B12 dietary sources and the 
importance of B12. All the participants involved in this 
exploratory study understood the burden of the inter-
vention and were eager to know about symptoms, treat-
ment and prognosis of B12 deficiency. Respondents were 
also willing to accept the intervention and the need for 
drawing extra blood from the baby as a part of routine 
sampling for B12 levels. Perceived barriers to the study 
included concerns around potential side effects of the 
B12 supplement, relocation mid- trial and financial diffi-
culties. All of these factors were considered in the study 
design, development of patient information, consultation 
and follow- up procedures as follows:
 ► All participants at the two study sites will be informed 
of the role, sources and importance of vitamin B12 in 
human health using educational banners and posters 
and through community workshops;
 ► The initial information about the trial will be given 
by the doctor providing antenatal care to the mother. 
Subsequent detailed consent and recruitment will be 
conducted by study research staff;
 ► In order to improve compliance and study retention, 
reminder text messages will be sent weekly to partici-
pating mothers;
 ► To avoid the risk of financial loss to participants, 
various biochemical tests at the Indian trial site will be 
sponsored, and transportation costs at the Nepal site 
will be covered;
 ► Bradleys’ Home Observation for Measurement of 
the Environment (HOME) inventory was added to 
the assessment given the divergent environmental 
profile of the two study sites,28 in order to assess the 
infant’s environment and possible environmental 
confounders on neurodevelopment.
The study results will be disseminated globally to 
academics and health professionals via conferences, pres-
entations and publications. Researchers at each study site 
will share results with participants during their follow- up 
visits.
Also, in preparation for this trial we adapted a prevali-
dated Food Frequency Questionnaire (FFQ) for vitamin 
B12 intake
29 to the Indian and Nepalese settings. In brief, 
the original vitamin B12 FFQ by Mearns
29 (including 
30 questions on consumption of food and beverages 
containing vitamin B12) was reviewed independently by 
two nutritionists. A market survey was done to obtain 
information on egg and milk products consumption, as 
well as the availability of B12 fortified items at local markets 
in Delhi and Kathmandu. Homemade recipes which 
included egg and/or dairy products as a main ingredient 
were incorporated into the FFQ. Measurements used in 
the FFQ were standardised based on the typical/locally 
available household utensils to ensure accurate responses 
and to maintain consistency across the sites.
All research staff from India and Nepal will be jointly 
trained in study design, research methodology, good clin-
ical practice, the study protocol and study tools. Training 
lectures will be video- recorded and made available to 
the teams at both study sites as a reference material for 
continuous training.
Eligibility
Potentially eligible participants will be screened at first 
presentation to the antenatal clinic at ≤12 weeks of gesta-
tion in accordance with the following criteria:
Inclusion criteria
 ► Consuming a vegetarian diet – including veganism 
and/or people who do eat egg and/or do consume 
milk and/or a portion meat/chicken/fish <once a 
month;
 ► Living within an a priori defined geographical area;
 – Delhi – national capital region;
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 – Nepal – 10 km radius of PMWH;
 ► Able to understand at least one of the following 
languages – English, Hindi or Nepalese.
Exclusion criteria
 ► Wish for medical termination of pregnancy;
 ► Aged <18 or >35 years;
 ► Already on medicinal vitamin B12 supplementation 
(including B- complex or multivitamins);
 ► Multiple gestation;
 ► Diagnosis of a chronic medical condition (including 
diabetes mellitus, hypertension, heart disease, neuro-
logical disease or thyroid disease);
 ► Testing positive for hepatitis B, HIV or syphilis;
 ► Anticipating moving out of the a priori defined 
geographical area before or after delivery;
 ► Undergoing treatment for infertility;
 ► Having a known pre- diagnosed mental health 
disorder, including depression, drug or alcohol abuse;
 ► Currently participating or having participated 
in another study within 4 weeks prior to the trial 
commencing;
 ► Having a known allergy to vitamin B12 or another 
supplement constituent.
Consent
Eligible participants meeting the selection criteria will 
be given time to think over continuation of pregnancy, 
site of delivery, participation in the trial and any other 
considerations. They will be contacted within 48 hours by 
the research team regarding their decision to participate, 
and will be invited to provide written or video- recorded 
consent. Participants will be able to opt into the trial any 
time before 12 weeks of gestation.
randomisation
As presented in figure 1, all eligible and consenting partic-
ipants will be randomised with an allocation ratio of 1:1 
to either the intervention (250 mcg) or control (50 mcg) 
group. The randomisation sequence will be generated 
at a single, third- party location (non- study site) using a 
computer- generated sequence stratified for location. The 
sequence will be allocated to serial numbers by a neutral 
person in each country using sequentially numbered, 
sealed, opaque envelopes. Codes within envelopes will 
identify boxes labelled with five- digit codes. Each box will 
contain enough dosages to cater to the study period of 
one participant. The strips containing intervention and 
control doses of B12 will be identical in taste, smell and 
appearance. All participants, recruiters, developmental 
therapists, laboratory staff and the data analyst will be 




Upon enrolment, demographic and clinical details, 
including age, height, weight, ethnicity, education and 
socioeconomic status, will be collected. The participants’ 
preferred channel of subsequent communication (phone, 
text message, email) will be noted. Participants will be 
allocated a study identification number and accompanied 
by the researcher for blood sampling. These samples will 
be taken at the same time as other samples being drawn 
in the first trimester to minimise unnecessary venepunc-
tures. Twelve mL of blood sample will be drawn into two 
plain vials (5 mL each) and 2 mL will be drawn into an 
EDTA vial. The EDTA sample will be processed immedi-
ately for complete blood counts by coulter counter. The 
plain (serum separator tubes) vial samples will be centri-
fuged at 3500 rpm (Rotor radius 15 cm) for 10 min at the 
study site. The separated serum will be transported on ice 
and consistently stored at −70°C, and will be monitored 
at both the study sites. Participants will be given enough 
B12 supplement doses to last 5 days beyond the expected 
date of their next visit, after being fully informed about 
the supplement and its administration. Participants will 
be contacted 48 hours after receiving the B12 doses to 
confirm initialisation of supplementation and re- empha-
sise compliance.
Subsequent maternal visits
Subsequent maternal visits will take place monthly until 
36 weeks, and then weekly thereafter. At these visits, all 
participants will visit their obstetrician as part of routine 
care. Participants will also meet with the research staff 
at a prespecified location at the study site. To maximise 
compliance, weekly adherence and pre- appointment 
reminders will be sent via the prespecified preferred 
mode of communication. Acquired morbidity (gesta-
tional diabetes, hypertension and hypothyroidism) and 
medication history will be noted in case record forms. 
Empty supplement packets will be collected at each 
appointment as an indicator of adherence. In the third 
trimester, mothers’ dietary B12 intake will be assessed 
using a pre- standardised and adapted FFQ, and blood 
sampling will be repeated using the same procedures as 
in the first trimester.
Neonatal assessment
During childbirth, a medical officer and/or paediatri-
cian will monitor the birth and post- delivery health of 
neonates for any morbidity that might potentially influ-
ence neurodevelopment. Gestational age, growth retarda-
tion, congenital abnormalities and APGAR (appearance, 
pulse, grimace, activity, respiration) score will be routinely 
documented for neonates. Cord pH will be measured for 
all newborns with a delayed cry and who require any inter-
vention beyond the basic steps of resuscitation (ambu 
bagging, intubation or pharmacological treatment). 
Any seizures, neurological problems, hypoglycaemia, 
hypothermia or hyperbilirubinaemia will be assessed, 
diagnosed, evaluated and managed as per institutional 
guidelines. As per standard practice, all newborns will be 
screened for hearing deficits, vision and critical congen-
ital heart disease according to institutional protocols. 
5Nagpal J, et al. BMJ Open 2020;10:e034987. doi:10.1136/bmjopen-2019-034987
Open access
Figure 1 Study design and participant flow through the study. CBC,complete blood count; DASII, Developmental Assessment 
Scales for Indian Infants; FFQ, Food Frequency Questionnaire; Hb,haemoglobin; HOME, Bradleys’ Home Observation for 
Measurement of the Environment; RBC, red blood cell; 25(OH)D, 25- hydroxyvitamin D.
Preterm neonates transferred to the neonatal unit will 
be monitored as per their customised follow- up and early 
intervention plans, implemented as recommended by the 
paediatrics and/or primary care provider. Neurodevelop-
ment and biochemical assessment of preterm neonates 
will be carried out as per their corrected gestational ages.
Infant follow-up
Infant follow- up will be conducted at 7 to 14 days, 4, 8, 
12 and 16 weeks and at 6 and 9 months of age. At these 
visits, the infants will undergo routine care as well as study 
specific evaluations (see Visit Schedule: online supple-
mentary table 1).
Routine care
Each mother- infant dyad will see a paediatrician for age- 
appropriate routine care, which will involve clinical eval-
uation, preventative care and vaccination as per standard 
procedures in each site. Anthropometric measurements 
and signs of micronutrient deficiency (anaemia and 
rickets) will be recorded during each visit as part of 
routine care. Metabolic disorders (congenital hypothy-
roidism, congenital adrenal hyperplasia, cystic fibrosis, 
biotinidase deficiency, phenylketonuria and galacto-
saemia) will be screened for and maternal support for 
breastfeeding by a paediatrician or lactation counsellor 
will be provided at 7 to 14 days.
Study specific
Supplements will be provided to mothers at each visit, 
with instructions to take until 6 months after childbirth. 
Any morbidities and deficiencies will be recorded and 
treated as per institutional guidelines. Maternal and 
infant tolerance for the supplementation, including any 
gastrointestinal symptoms, will be recorded at each visit, 
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as will maternal compliance. Provision of supplements to 
the mother in both groups will be stopped at 6 months 
post- partum.
The hospital evaluation at 9 months (±14 days) will 
include neurodevelopmental assessment by a develop-
mental therapist using the Developmental Assessment 
Scales for Indian Infants (DASII)—an adapted and vali-
dated version of the Bayley’s Scale for Infant Development 
Third Edition30—and blood sampling for estimation of 
haemoglobin, vitamin B12, homocysteine and holotransco-
balamin concentrations. The DASII motor scale assesses 
gross and fine motor skills, while cognitive, personal and 
social skills development are assessed through the DASII 
mental scale. All neurodevelopmental assessments will be 
conducted by a trained developmental therapist at the 
institution in a soundproof room. In premature babies, 
corrected gestational age will be used to calculate devel-
opmental quotients. Additional assessments will include a 
complementary feeding assessment by a nutritionist using 
a 72 hours dietary recall, and a home environment assess-
ment using the adapted Bradley HOME inventory28 by a 
trained field worker.
Compliance
Research staff will dispense blister packaging of 10 B12 
capsules and study specific bags for participants to store, 
carry and keep supplements in one place. In case of loss 
of supplement or inability to come for follow- up, partic-
ipants will be able to contact the researcher at any time 
to request more supplements. The supplement pack-
aging will be numbered with a serial number. To maxi-
mise compliance, weekly reminders will be sent through 
the preferred mode of communication as specified by 
the trial participants. Each participant will be provided 
with a bag to save empty packaging strips and instructed 
to carry the bag with her at the next visit to monitor 
compliance.
biochemical analysis
All saved samples will be processed as one batch after the 
completion of the study. The maternal samples will be used 
to determine the blood levels for vitamin B12, homocys-
teine, holotranscobalamin, 25- hydroxyvitaminD (25(OH)
D), folate, iron studies (serum iron, ferritin and total iron 
binding capacity), complete blood count (CBC) and red 
blood cell (RBC) indices in the first and third trimesters. 
Infant blood will be used for haemoglobin, vitamin B12, 
homocysteine and holotranscobalamin measurements. 
Vitamin B12 and 25(OH)D will be measured by enhanced 
chemiluminescenceimmunoassay (CLIA) (Johnson & 
Johnson, USA). Iron levels will be estimated by pyridylazo 
dye (Johnson & Johnson, USA). Folate will be analysed 
by enhanced CLIA (Beckman Coulter, USA) and CBC 
(Beckman Coulter, USA). RBC indices will be calculated 
by impedance (Beckman Coulter, USA). Homocysteine 
and holotranscobalamin will be analysed by chemilumi-
nescent microparticle immunoassay.
outcomes
The following study outcomes will be investigated:
Primary outcome
 ► DASII scores for infants at 9 months (±2 weeks) 
post- partum.
Secondary outcome(s)
 ► Change in B12 status (vitamin B12 level, homocyst-
eine and holotranscobalamin) of mother between 
first (≤12 weeks’ gestation) and third trimester (≥27 
weeks’ gestation);
 ► B12 status (vitamin B12 level, homocysteine and 
holotranscobalamin) of infants at 9 months (±2 
weeks) post- partum.
Exploratory outcome(s)
 ► Haemoglobin of infants at 9 months (±14 days) 
post- partum;
 ► Infant anthropometry including weight, height/
length and head circumference at 9 months after 
birth in all subjects.
sample size considerations
A planned sample of 720 pregnant women, 360 per study 
site, will be randomly assigned to experimental (n=360; 
n=180 in per study site) or control (n=360; n=180 in 
per study site) groups. This is based on the number of 
infants needed to complete the neurodevelopmental 
screen in each of the two randomised groups to detect 
a difference in development quotient (DQ) at 9 months 
(primary outcome) of two points (presumed mean DQ in 
this population of infants at 9 months of 96.9, SD 7.07 on 
basis of earlier work).27 The difference of two DQ points 
was chosen because it is the smallest effect size thought 
to be clinically significant, and hence a null trial result 
is likely to exclude a clinically relevant effect of maternal 
B12 supplementation on infant cognitive function. The 
sample size has been inflated by 35% to account for attri-
tion, and assumes 90% statistical power and a 5% two- 
sided significance level.
statistical analysis
The primary and secondary outcomes will be analysed 
using an intention- to- treat analysis by a blinded statis-
tician. Comparability of participants assigned to study 
groups at enrolment will be assessed using tests of asso-
ciation for categorical variables and by fitting generalised 
linear models for continuous variables. These models will 
include interaction terms to explore conditional differ-
ences between the trial’s arms. If necessary, transforma-
tions will be applied to the response variables to fulfil the 
model’s assumptions. Covariates will include trial site, 
infant feeding, gender, feeding by gender, weight z- score 
at birth, weight gain between birth and 3 months and 
maternal body mass index. Z- scores for height and weight 
will be calculated according to the WHO31 growth stan-
dards using the R language for statistical computing.32
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Subgroup analysis will be conducted to examine the 
differential impact of B12 supplementation in high versus 
low risk mothers and infants. Mothers identified as having 
pregnancy- related or other morbidity will be classified as 
high- risk (eg, including gestational diabetes, pregnancy- 
induced hypertension/pre- eclampsia/eclampsia and 
absent or reversed end diastolic flow); and low- risk. Babies 
will be defined as high risk if there is any combination of 
the following:
 ► Small for gestational age, defined as <10th centile for 
birth weight;
 ► Very preterm (28 to 32 weeks gestation); extremely 
preterm babies (<28 weeks) will be excluded from the 
analysis;
 ► Experience of a higher risk neonatal course defined 
as experience of APGAR score <7 at 1 min, hypogly-
caemia, hyperbilirubinaemia or prolonged neonatal 
intensive care stay >7 days);
 ► Infants with documented neurological disease/
anomaly/illness will be subgrouped separately (high 
risk) and compared with those with no disease/
anomaly illness (low risk).
data management and dissemination
Data will be collected under the regulation of the data 
protection and management guidelines provided by the 
Governments of India and Nepal, and as per the UK 
Data Protection Act 2018. Data will be securely stored 
in an E- database with password protection. The E- data-
base will be designed using Access. Live data entry will 
be conducted at the study sites and tested for accuracy 
using duplicate data entry at an offsite location at peri-
odic intervals.
The study results will be disseminated globally with 
academic and health professionals via conferences, 
presentations and publications. Researchers at each 
study site will share emerging results with participants 
during their follow- up visits. Regular site meetings with 
press offices, short films, radio spots, periodic blog posts 
and Twitter and Facebook messages are also planned to 
strengthen the trial’s online presence and reach young 
and middle- aged Internet users for whom the informa-
tion may be of interest.
Qualitative evaluation
A qualitative analysis of the information learnt during 
preliminary PPI work aimed to explore knowledge, atti-
tudes and perceptions of pregnant women towards B12 
supplementation and child development and the poten-
tial barriers to implementation. Better understanding 
these domains across the two study sites informed the 
perceived need for the intervention, helped define 
patient- centric outcomes and allowed the evaluation of 
any differences between the two arms.
We used convenience sampling to recruit and inter-
view 25 participants across both trial sites (SBISR 12; 
PMWH 13). We developed and piloted a semi- structured 
topic guide in collaboration with our PPI representatives 
serving on the Trial Steering Committee. The topic guide 
was designed in English and translated into either Hindi 
or Nepali. The topic guide was then back- translated into 
English to ensure consistency and accuracy of content. 
It was created with the intention to help direct the inter-
view while remaining sensitive to unsolicited themes. 
We ensured that an interviewer with prior training and 
experience in qualitative methods facilitated the semi- 
structured interviews.
Data was collected in quiet rooms in each hospital, 
away from other patients and staff. Interviews were facil-
itated in English, Hindi or Nepalese, depending on the 
preference of the participant. All interviews were audio- 
recorded, transcribed, translated into English (where 
necessary) and then cross- checked against the original 
recording. The translated transcripts were then coded 
using the  ATLAS. ti 7.2 software for qualitative analysis.33 
A research team member coded and categorised the data, 
and prepared an initial narrative. A report detailing the 
findings is in the process of being finalised, with input 
from the interviewers and wider research team.
Ethical considerations
The study protocol (10th December 2018. Version: 8.0), 
informed consent form, participant information sheet, 
tool and other supportive materials have been approved 
by the Institutional Ethics Committee (IEC) at SBISR 
(FL/SBISR/IEC/2018–01); Public Health Foundation 
of India (TRC- IEC-380/18); PMWH (59-11-433); Nepal 
Health Research Council Ethical Review Board (Reg No. 
761/2018) and the University College London Research 
Ethics Committee (10901/001). The investigators at 
each study site have submitted to, and where necessary, 
obtained approval from the above parties for all substan-
tial amendments to the original approved documents.
The trial will be conducted in accordance with the prin-
ciples and rules of the Declaration of Helsinki. Informed 
and written consent will be obtained from all participants 
by the research teams at each study site. The trial will 
comply with the UK Data Protection Act 2018, ensuring 
the participants’ anonymity. The participants will be iden-
tified only by a participant identification number on all 
trial documents and electronic databases. Every effort 
will be made to arrange interviews and examinations at 
a time convenient to the participants, without causing 
much disruption in their daily routine. Study data will 
be stored securely and will only be accessible to trial staff 
and authorised personnel. The Principal Investigator at 
each study site will submit an annual progress report, end 
of trial notification and a final report to the Institutional 
Ethics Committee, host organisations and the funders.
We used the Standard Protocol Items: Recommenda-
tions for Interventional Trials checklist for writing our 
protocol.34
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dIsCussIon
A positive result from this study will have considerable 
impact on current and future policy initiatives, by under-
pinning current micronutrient supplementation policy 
in India and Nepal. The project will provide key insights 
to strengthen existing Indian governmental nutrition 
programmes such as ‘National Iron Plus Initiative’, 
‘Janani Suraksha Yojana’ and ‘Janani Shishu Suraksha 
Karyakaram’. Because of the high worldwide prevalence 
of maternal B12 deficiency (74%), the study findings will 
also be highly relevant to maternal and neonatal health in 
nutritionally vulnerable and at- risk populations globally.
Using a 50 mcg quasi- control group limits the infer-
ences that can be drawn from a negative result (neuro-
development comparable between the two groups). The 
study outcome could produce several results, which could 
be interpreted as follows:
1. Findings: Improvement in B12 parameters from first 
trimester to third trimester is statistically significant in 
both groups, and the change is statistically comparable 
between two groups for mother and baby. Substantial 
proportion of mother/infants in both groups improve 
from B12 deficient to replete state.
Interpretation: 250 mcg dose is as effective as 50 mcg in 
improving biochemical parameters and both doses re-
sult in comparable neurodevelopment. 250 mcg dos-
ing offers no additional advantage over 50 mcg.
2. Findings: Improvement in B12 parameters from first 
trimester to third trimester is significant in either 250 
mcg alone or both groups, but 250 mcg causes higher 
rise (statistically significant) in B12 biochemical param-
eters than 50 mcg for mother and baby.
Interpretation: 250 mcg is more efficacious than 50 mcg 
in improving biochemical B12 status. Since neurode-
velopment is equivalent between two groups a higher 
dose of supplementation does not offer any neurode-
velopmental advantage despite better biochemical B12 
status.
3. Findings: A lack of biochemical improvement in both 
groups, although unexpected, would be interpreted 
to mean poor efficacy of 50 mcg or 250 mcg oral B12 
in improving B12 status of mother- infant pairs. Both 
groups continue to have a high proportion of mothers 
deficient in B12 before and after supplementation.
Interpretation: Factors affecting B12 status in the current 
trial (including compliance and socio- demographics) 
would have to be carefully analysed. Further work 
would be required to study the determinants of oral 
B12 efficacy in detail.
Many studies have evaluated the impact of varying 
vitamin B12 intake (physiological dosage (2 mcg/day) to 
pharmacological dosage (up to 2000 mcg/day); supple-
mented/observed) in diverse population sets.20–24 35 Our 
study specifically seeks to address the question of the 
optimum dosage for vegetarian pregnant women. As 
one of the few large- scale trials of B12 supplementation in 
pregnancy, the results of this study would be generalisable 
to vegetarian expecting mothers. We aim to contribute 
to the evidence base on improving neurodevelopmental 
outcomes in vulnerable infants. While a positive outcome 
for the trial would help to develop an intervention 
programme to reduce developmental delay using vitamin 
B12 as a supplementation in pregnant women, a negative 
or null result would also add to existing knowledge and 
lay the groundwork for future work on the subject—espe-
cially around utility, dose, duration and time of initiation 
of vitamin B12 supplementation.
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